EE345 Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2-Months Is Cost Effective for the Treatment of HIV-1 in Spain

Current antiretroviral therapy (ART) improves health outcomes, but for some people with HIV daily oral administration remains a challenge. Cabotegravir+rilpivirine long-acting (CAB+RPV LA), administered by a healthcare professional via intramuscular injection every 2 months (Q2M), is the first complete LA regimen for the maintenance treatment of HIV to be available in Spain. The objective of this analysis was to evaluate the cost-effectiveness of CAB+RPV LA Q2M compared with daily oral single tablet regimen (STR) ART in Spain, from the National Healthcare System (NHS) perspective.